Navigation Links
Tourette Syndrome Association and Psyadon Pharmaceuticals to Collaborate on a Drug Trial for Tourette Syndrome Treatment
Date:5/11/2011

BAYSIDE, N.Y. and GERMANTOWN, Md., May 11, 2011 /PRNewswire-USNewswire/ -- The national Tourette Syndrome Association (TSA) and Psyadon Pharmaceuticals Inc. are pleased to announce their collaboration on a clinical trial to determine the potential efficacy of a novel drug, ecopipam, for managing the symptoms of the neurological disorder Tourette Syndrome (TS).

"This is the first time in our 39-year history that TSA has collaborated with the pharmaceutical industry and helped to fund a clinical drug trial for the potential treatment of TS. It marks the beginning of a new phase in our efforts to facilitate the development of effective and safe medications that are urgently needed for people with TS," said Judit Ungar, President of the NY-based not-for-profit organization.

The TSA will also assist with subject recruitment for the clinical trial of ecopipam, the rights to which are owned by Psyadon.

Marked by involuntary movements and sounds called "tics," TS is an inherited, neurobiological disorder frequently misunderstood by the public and often misdiagnosed medically.

Various off-label drugs are prescribed by medical professionals for TS, but of these, only two — pimozide and haloperidol — are approved by the FDA for the treatment of TS. These medications often provide only mild to moderate benefit and have poorly tolerated side effects that limit their use.

The FDA granted ecopipam an orphan-drug designation for the treatment of TS in September 2010. Richard Chipkin, President and CEO of Psyadon, stated, "We are honored to be selected as the first company the TSA has collaborated with on a clinical drug study. Experiments in animals suggest that ecopipam, which belongs to a class of agents referred to as dopamine D1 antagonists, interacts with nerve cells and systems in the brain that are thought to contribute to the development of tics and other symptoms in TS. Based on these studies, there is a good rationale and a logical basis for examining this drug's efficacy in reducing tic severity in individuals with TS."

The clinical trial, which has already begun, is a Phase 2a, open-label, non-randomized trial to examine the ability of ecopipam to both reduce tic severity and also to determine its safety in individuals (18 to 65 years of age) with TS. The study is being conducted at four sites across the U.S. by leading experts in the field of TS and is expected to last for several months. Further information on the clinical trial can be found at www.clinicaltrials.gov.

This study is designed, and will be conducted with safety being a top priority. It will be jointly monitored by TSA and Psyadon, and an independent Drug Safety Monitoring Board will be responsible for an impartial evaluation of the study.

"Neither ecopipam nor any other drug with a similar mechanism has been tested in TS. Therefore, the results of this study will be immensely valuable. The TSA-Psyadon collaboration sets the precedent for our future partnerships with the pharmaceutical industry," said Dr. Kevin McNaught, Vice President for TSA Medical and Scientific Programs.

Psyadon and TSA anticipate the data from this clinical trial will be released by mid-2012.

About TSA

Founded in 1972, TSA is a national voluntary organization with a three-pronged mission of education, research and service. TSA directs a network of over 33 chapters and more than 150 support groups across the country. For more information on TS, call 1-888-4-TOURET or visit http://tsa-usa.org.

About Psyadon Pharmaceuticals

Psyadon Pharmaceuticals, Inc. is a company that develops drugs for the treatment of diseases afflicting the central nervous system.  Founded in 2008, the firm is based in Germantown, Maryland. It receives financial support from New Enterprise Associates (Chevy Chase, MD) whose partner, Dr. James Barrett, acts as the Chairman of Psyadon's Board of Directors. For more information, visit www.psyadonrx.com.

Media Contacts:
TSA: Tracy Colletti-Flynn tracy.flynn@tsa-usa.org, 1-718-224-2999
Psyadon: Richard Chipkin  info@psyadonrx.com


'/>"/>
SOURCE Tourette Syndrome Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patients Living with Sjogrens Syndrome Encourage Communities to "Defy the Dry"
2. New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease
3. New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment
4. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
5. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
6. FDA Approves Horizant To Treat Restless Legs Syndrome
7. JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome
8. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
9. For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019
10. Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
11. VSL#3® Probiotic Shown Effective in Dietary Management of Children With Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... a CAGR of around 8.2% over the next decade ... the prominent trends that the market is witnessing include ... portable nebulizers, recent technological advancements in nebulizer products and ... on device type the market is categorized into pneumatic ...
(Date:1/17/2017)... Calif. , Jan. 17, 2017  Edwards Lifesciences ... in patient-focused innovations for structural heart disease and critical ... the quarter ended December 31, 2016 after the market ... a conference call at 5:00 p.m. ET that day ... the conference call, dial (877) 407-8037 or (201) 689-8037.  ...
(Date:1/17/2017)... Calif. and KANSAS CITY, ... Children,s Hospitals Neonatal Consortium (CHNC) has selected Velos ... their visionary data management and multicenter initiatives. ... organization comprised of 32 Neonatal Intensive Care Units ... America . The consortium provides a benchmark ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research ... Association of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim ... has long been the gold standard for high-definition, in-ear earphones. This classic earphone ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... County, as well as Palm Desert, is opening a new office in San ... deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... accredited, online continuing education for EMS and firefighting professionals, has released four new ... Solution. These new courses are taught live in an online classroom and meet ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
Breaking Medicine News(10 mins):